<DOC>
	<DOCNO>NCT01165996</DOCNO>
	<brief_summary>RATIONALE : Decitabine may help myelodysplastic cell become like normal stem cell . PURPOSE : This clinical trial study differentiation therapy decitabine treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Differentiation Therapy With Decitabine Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Demonstrate differentiation therapy DNMT1 deplete non-DNA damaging dos decitabine efficacious administered weekly &gt; = 12 month . SECONDARY OBJECTIVES : I. Assess safety regimen . II . Retrospectively compare study standard regimen clinical response . III . Assess ability pharmacodynamic assay measure DNMT1 depletion peripheral blood white blood cell predict clinical response decitabine . IV . Assess PCR aberrant methylation signature early marker relapse . V. Identify biologic feature MDS correlate response decitabine , thereby facilitate future patient selection . VI . In case relapse resistance , assess role enzyme CDA alter decitabine metabolism prevent DNMT1 depletion . OUTLINE : INDUCTION PHASE : Patients receive decitabine subcutaneously ( SC ) twice weekly 4 week thrice weekly achieve bone marrow blast &lt; 5 % . MAINTENANCE PHASE : Patients receive decitabine SC twice weekly 52 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion MDS classify hematopathology review WHO categories refractory anemia ( RA ) refractory cytopenia multilineage dysplasia ( RCMD ) refractory anemia ring sideroblast ( RARS ) refractory anemia excess blast ( RAEB1 RAEB2 ) chronic myelomonocytic leukemia ( CMML1 CMML2 ) Symptomatic anemia OR thrombocytopenia platelet count &lt; 100 x 10^9/L OR transfusion dependence redcells OR transfusion dependence platelet OR absolute neutrophil count &lt; 1 x 10^9/L Exclusion MDS WHO subtypes RA RCMD sole 5q abnormality cytogenetics unless fail lenalidomide ( Revlimid ) therapy Previous treatment decitabine Untreated erythropoietin deficiency define erythropoietin level &lt; 200 IU/L erythropoietin replacement therapy &lt; 8 week ( erythropoietin deficiency correct ) Uncontrolled infection Severe sepsis septic shock Current pregnancy breast feed The patient childbearing age , unwilling use contraception tubal ligation , hysterectomy , vasectomy , partner also unwilling use acceptable method contraception determine investigator Not able give inform consent Altered mental status seizure disorder ALT &gt; 300 IU ; albumin &lt; 2.0 mg/dL Creatinine &gt; 2.5 mg/dl creatinine clearance &lt; 60ml/min B12 , folate , iron deficient , correct NYHA class III/IV status ECOG performance status &gt; 2 HIV positive history seropositivity HIV Transformation acute leukemia ( &gt; = 20 % myeloblast marrow aspirate ) Any experimental agent study drug decitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>